J
Jorge Sabbaga
Researcher at University of São Paulo
Publications - 47
Citations - 2869
Jorge Sabbaga is an academic researcher from University of São Paulo. The author has contributed to research in topics: Colorectal cancer & Neoadjuvant therapy. The author has an hindex of 13, co-authored 43 publications receiving 2393 citations. Previous affiliations of Jorge Sabbaga include Adma.
Papers
More filters
Journal ArticleDOI
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Angelita Habr-Gama,Rodrigo Oliva Perez,Wladimir Nadalin,Jorge Sabbaga,Ulysses Ribeiro,Afonso Henrique da Silva e Sousa,Fábio Campos,Desidério Roberto Kiss,Joaquim Gama-Rodrigues +8 more
TL;DR: Stage 0 rectal cancer disease is associated with excellent long-term results irrespective of treatment strategy and Surgical resection may not lead to improved outcome in this situation and may be associated with high rates of temporary or definitive stoma construction and unnecessary morbidity and mortality rates.
Journal ArticleDOI
Watch and Wait Approach Following Extended Neoadjuvant Chemoradiation for Distal Rectal Cancer: Are We Getting Closer to Anal Cancer Management?
Angelita Habr-Gama,Jorge Sabbaga,Joaquim Gama-Rodrigues,Guilherme Pagin São Julião,Igor Proscurshim,Patricia Bailão Aguilar,Wladimir Nadalin,Rodrigo Oliva Perez +7 more
TL;DR: Extended chemoradiation therapy with additional chemotherapy cycles and 54 Gy of radiation may result in over 50% of sustained (>12 months) complete clinical response rates that may ultimately avoid radical rectal resection.
Journal ArticleDOI
Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice.
Luis Felipe Campesato,Romualdo Barroso-Sousa,Leandro Jimenez,Bruna R. Correa,Jorge Sabbaga,Paulo M. Hoff,Luiz F. L. Reis,Pedro A. F. Galante,Anamaria A. Camargo +8 more
TL;DR: The data reveals that CGPs can be used to estimate mutational load and to predict clinical benefit to PD-1 blockade, with similar accuracy to that reported using WES.
Journal ArticleDOI
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
Angelita Habr-Gama,Rodrigo Oliva Perez,Jorge Sabbaga,Wladimir Nadalin,Guilherme Pagin São Julião,Joaquim Gama-Rodrigues +5 more
TL;DR: The addition of chemotherapy during the resting period after neoadjuvant chemoradiation is associated with acceptable toxicity and high tolerability rates.
Journal ArticleDOI
Organ Preservation in cT2N0 Rectal Cancer After Neoadjuvant Chemoradiation Therapy: The Impact of Radiation Therapy Dose-escalation and Consolidation Chemotherapy.
Angelita Habr-Gama,Guilherme Pagin São Julião,Bruna Borba Vailati,Jorge Sabbaga,Patricia Bailão Aguilar,Laura M. Fernandez,Sergio Eduardo Alonso Araujo,Rodrigo Oliva Perez,Rodrigo Oliva Perez +8 more
TL;DR: Dose-escalation and consolidation chemotherapy leads to increased long-term organ-preservation rates among cT2N0 rectal cancer patients undergoing 2 different chemoradiation (CRT) regimens.